🔎 Trials Near Me

Utama › Sindrom Mielodisplastik › New Hampshire

Kajian klinikal Sindrom Mielodisplastik di New Hampshire

5 kajian untuk Sindrom Mielodisplastik sedang mencari peserta di lokasi di New Hampshire.

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06577441

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

  • Dartmouth-Hitchcock, Lebanon
Mengambil pesertaKajian pemerhatian
Sehingga umur 30 · Semua jantina · Dikemas kini 16 Jul 2026 · NCT04968834

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

  • Dana Farber/New Hampshire Oncology-Hematology, Londonderry
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2026 · NCT02269592

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.